Science & Technology
Developing RNA therapeutics for rare neurodevelopmental disorders
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R42HD111138-02
Award Ceiling
$854K
Award Floor
$854K
Close Date
Dec 31, 2026
291 days leftTotal Funding
$854K
Expected Awards
1
Posted Date
Jan 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-4R42HD111138-02
Description
STTR Phase Phase II award: "Developing RNA therapeutics for rare neurodevelopmental disorders" awarded to Dayi Therapeutics, Inc. in College Station, Texas. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $853,987. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.